Nintedanib Sandoz

Nintedanib, the active ingredient in Nintedanib Sandoz, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis and systemic sclerosis‑associated interstitial lung disease, helping to slow disease progression in adult patients.

GNH USA supplies Nintedanib Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory compliance across multiple markets. The company ensures consistent batch release and on‑time delivery to meet clinical demand.

Nintedanib is an antifibrotic agent that targets key pathways involved in lung fibrosis. - Idiopathic pulmonary fibrosis: slows the decline in forced vital capacity and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: limits further loss of lung function and delays worsening of fibrosis.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, sometimes accompanied by vomiting. - Decreased appetite: reduced desire to eat, may lead to weight loss. - Elevated liver enzymes: mild increases in ALT/AST observed in routine labs.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring and possible discontinuation. - Severe bleeding: gastrointestinal or other hemorrhage, especially with anticoagulants. - Cardiovascular events: myocardial infarction or stroke in susceptible patients. - Interstitial lung disease worsening: acute exacerbation of underlying lung condition. - Severe infections: opportunistic infections in immunocompromised individuals.

Before initiating therapy, clinicians should evaluate several safety considerations. - Liver function monitoring: obtain baseline ALT/AST and repeat periodically. - Bleeding risk assessment: review concomitant anticoagulants or antiplatelet agents. - Pregnancy: avoid use because safety data are lacking; discuss contraception. - Drug interactions: assess for strong CYP3A4 inhibitors or inducers that may alter exposure. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nintedanib can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and toxicity. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of serious bleeding.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may modestly raise exposure. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness by lowering drug levels. - Antacids or proton‑pump inhibitors: could affect absorption; monitor clinical response.